会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 8. 发明申请
    • IDENTIFICATION AND USE OF PROGNOSTIC AND PREDICTIVE MARKERS IN CANCER TREATMENT
    • 癌症治疗中预防和预防标记的鉴定与使用
    • WO2009148593A1
    • 2009-12-10
    • PCT/US2009/003382
    • 2009-06-02
    • NSABP FOUNDATION, INC.PAIK, SoonmyungKIM, Chungyeul
    • PAIK, SoonmyungKIM, Chungyeul
    • C12Q1/68A61K39/395A61P35/00
    • A61K31/704A61K31/337A61K31/675A61K39/39558C12Q1/6841C12Q1/6886C12Q2600/106A61K2300/00
    • The present invention provides a method of screening for markers useful in predicting the efficacy of a specified cancer that includes: (a) constructing a tissue microarray from a tissue bank comprising multiple tissue samples that are annotated with clinical follow up data; (b) labeling polynucleic acid probes specific for oncogenes or cancer associated genes known to be potential amplicons; (c) performing fluorescent in situ hybridization analysis on the tissue microarray; and (d) correlating the result of the fluorescent in situ hybridization with the clinical follow up data. The present disclosure also provides methods of treating breast cancer that include screening a breast cancer patient for amplification of one or more of the genes disclosed herein, and treating a patient having amplification of one or more of these genes with a therapeutically effective amount of a compound that interferes with HER2 signaling.
    • 本发明提供筛选用于预测特定癌症功效的标志物的方法,其包括:(a)从包含多个组织样本的组织库构建组织微阵列,所述多个组织样本用临床跟踪数据注释; (b)标记针对致癌基因或已知为潜在扩增子的癌症相关基因特异性的多核酸探针; (c)对组织微阵列进行荧光原位杂交分析; 和(d)将荧光原位杂交的结果与临床随访数据相关联。 本公开还提供了治疗乳腺癌的方法,其包括筛选乳腺癌患者以扩增本文公开的一种或多种基因,并用治疗有效量的化合物治疗具有这些基因中的一种或多种的扩增的患者 这干扰了HER2信号。
    • 9. 发明申请
    • IDENTIFICATION AND USE OF PROGNOSTIC AND PREDICTIVE MARKERS IN CANCER TREATMENT
    • 在癌症治疗中识别和使用预测性和预测性标志物
    • WO2006065940A2
    • 2006-06-22
    • PCT/US2005/045322
    • 2005-12-15
    • NSABP FOUNDATION, INC.PAIK, SoonmyungKIM, Chungyeul
    • PAIK, SoonmyungKIM, Chungyeul
    • C12Q1/68G01N33/574
    • G01N33/5082C12Q1/6886C12Q2600/106C12Q2600/158G01N33/574G01N33/57415G01N33/57492G01N33/6845G01N2500/00
    • The present invention provides a method of screening for markers useful in predicting the efficacy of a specified cancer that includes: (a) constructing a tissue microarray from a tissue bank comprising multiple tissue samples that are annotated with clinical follow up data; (b) labeling polynucleic acid probes specific for oncogenes or cancer associated genes known to be potential amplicons; (c) performing fluorescent in situ hybridization analysis on the tissue microarray; and (d) correlating the result of the fluorescent in situ hybridization with the clinical follow up data. In addition, the present invention provides a method of treating breast cancer that includes measuring the expression levels or amplification of HTPAP in a patient having breast cancer and then providing a patient having increased levels of HTPAP expression or HTPAP amplification with therapeutic quantities of at least one compound that interferes with the phosphatidic acid phosphatase activity of HTPAP. The present invention also encompasses a method of treating breast cancer that includes screening a breast cancer patient for amplification of the cMYC gene and then treating a patient having amplification of the cMYC gene with therapeutic quantities of a compound that interferes with HER2 signaling.
    • 本发明提供筛选可用于预测特定癌症功效的标志物的方法,所述方法包括:(a)从包含多个组织样本的组织库构建组织样本,所述组织样本用临床 跟进数据; (b)标记对已知为潜在扩增子的致癌基因或癌症相关基因特异性的多核苷酸探针; (c)对组织微阵列进行荧光原位杂交分析; 和(d)将荧光原位杂交的结果与临床随访数据相关联。 此外,本发明提供了治疗乳腺癌的方法,其包括测量患有乳腺癌的患者中的HTPAP的表达水平或扩增,然后提供具有增加水平的HTPAP表达或HTPAP扩增的患者,其治疗量为至少一种 干扰HTPAP的磷脂酸磷酸酶活性的化合物。 本发明还包括治疗乳腺癌的方法,包括筛选乳腺癌患者扩增cMYC基因,然后用治疗量的干扰HER2信号传导的化合物治疗患有cMYC基因扩增的患者。